Resume for Raymond J. Winquist, Ph.D., F.A.H.A.

196 Carolyn Circle 203-910-7106Marshfield, MA 02050 winquist@aol.com

Dynamic executive-level Research Leader with extensive drug discovery experience and proven track record in both Biotech and large Pharmaceutical companies. Scientific strengths include pharmacology, molecular/cellular and systems biology, immunology, oversight of diverse platforms such as ion channels, epigenetics, kinases, and stem cells. Deep experience in many therapeutic areas including cardiovascular, oncology, CNS, respiratory, liver and gastrointestinal. Leadership strengths include developing and implementing research strategies, motivating/inspiring/mentoring emerging leaders, and building highly effective interdisciplinary teams to address challenging biological questions and to advance drug discovery programs. Management strengths include budget oversight responsibilities (department budget of $25 million), career development, team-building, communication, and listening.

EXPERIENCE

Vertex Pharmaceuticals Inc, Cambridge/Boston MA 2005 to 2015Co-Site Head of Research; Vice President of Integrated Biology (2012-2015)Effectively supervised Department of Integrated Biology (approximately 100 FTEs) and provided guidance for drug discovery research projects (co-site head) at the Cambridge/Boston facility.

Represented Cambridge/Boston research on Vertex Global Project Steering Committee. Associated with progressing two molecules into clinical trials; progressed 2 molecules towards

GLP tox studies (4Q2015); progressed one project into Lead Optimization (4Q2015). Designed new group (Exploratory BioChemistry) to pursue intrinsically disordered proteins for

drug discovery targets. Led Vivarium team for submitting Program Description (and successful site visit) for AAALAC

accreditation. Provided Research expertise on Business Development teams assessing possible in-licensing

candidates.

Vice President of Pharmacology (2005 to 2010); Vice President of Integrated Biology (2010 to 2015)Effectively supervised Department of Pharmacology (approximately 50 FTEs) then accepted responsibility for supervising Dept of Integrated Biology (combined Pharmacology and Biology). Provided guidance for drug discovery research projects and external research collaborations.

Developed a focused department of Pharmacology for more efficient/effective support of projects.

Initiated focus on human relevant cell/tissue assays for Oncology and Neurobiology projects. Created research strategy for Vertex approach in Multiple Sclerosis (remyelination). Associated with progressing five molecules into GLP toxicology and 2 molecules into clinical

trials. Represented Cambridge Research on Vertex Global Project Steering Committee, on external

research collaborations and on Business Development teams for possible in-licensing opportunities.

Scion Pharmaceuticals Inc, Medford, MA 2003 to 2005Vice President of Pharmacology

Supervision of in-house DMPK and Pharmacology (approximately 6 FTEs) to support Discovery Programs of novel ion channel blockers for Neuropathic Pain and Atrial Fibrillation; responsible for executing and supervising work packages contracted with external laboratories for assessment of preclinical efficacy, Safety Pharmacology and Toxicology including IND-enabling studies.

Active member of Senior Management Team which created R&D strategies, evaluated possible in-licensing candidates, and presented strategies/updates to the Board of Directors, possible investor groups and corporate partners.

Devised Clinical Development Plans (P1; P2) for our assets and possible in-licensing molecules (Ventricular Fibrillation; Post-Operative/ Neuropathic Pain; IBS, ED). Organized Clinical Expert meetings to discuss strategies for refining development plans in Neuropathic Pain. Participated and presented at pre-IND meeting with the FDA.

Associated with one molecule which reached IND status (open IND).

ADDITIONAL RELATED EXPERIENCE

Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield CTDirector of Pharmacology

Merck Sharpe and Dohme Research Laboratories, West Point PAResearch Fellow, Pharmacology

EDUCATION

NIH Postdoctoral Fellowship, PhysiologyUniversity of Michigan Medical School

Ph.D., PharmacologyUniversity of California, Los Angeles

Masters in Scientific Instrumentation, Physics DepartmentUniversity of California, Santa Barbara

Bachelor of Arts, Biological SciencesUniversity of California, Santa Barbara

PROFESSIONAL AFFILIATIONS

Fellow of the American Heart Association, Council on High Blood Pressure ResearchAssociate Editor, Journal of Pharmacology and Experimental Therapeutics

Editorial Board, Biochemical Pharmacology

PUBLICATIONS

Approximately 70 papers published in peer reviewed journals; 22 book chapters.

- 2 -

FULL CURRICULUM VITAE

RAYMOND J. WINQUIST, Ph.D., F.A.H.A.

Education

1967-1971 University of California, Santa BarbaraB.A., Biological Sciences

1971 (summer) The Marine Biological Laboratory, Woods Hole, MA Research Associate

1971-1973 University of California, Santa BarbaraDepartment of Biological SciencesGraduate Student and Teaching Assistant

1973-1975 University of California, Santa BarbaraDepartment of Physics Scientific Instrumentation ProgramM.S. in Scientific Instrumentation

1975-1979 University of California, Los AngelesDepartment of PharmacologyPh.D., Pharmacology

Postgraduate Training

Dec. 1979-1981 University of Michigan Department of PhysiologyPostdoctoral Scholar

Funding

1976-1979 NIH Predoctoral Trainee Department of PharmacologyUniversity of California (Los Angeles)

1979-1981 NIH Postdoctoral Fellowship Department of Physiology

- 3 -

University of Michigan

Awards & Prizes

1983 Finalist, A.N. Richards Young Investigators Competition Philadelphia Physiological Society

1984 Finalist, A.N. Richards Young Investigators CompetitionPhiladelphia Physiological Society

1994 Vice President's Award, Boehringer Ingelheim, for Directing the Pharmacological Effort in the Company's Research in Identifying Inhibitors of the Renin/Angiotensin System

Professional Experience

6/1981 - 6/1984 Senior Research PharmacologistMerck Sharp & Dohme Research Laboratories (West Point, PA)RESPONSIBILITIES:Supervision of vascular biology laboratory to support drug-discovery programs in Cardiovascular (Hypertension, Heart Failure, Stroke). Development of assays for initiation of discovery programs in modulators of calcium and potassium channels and ion co-transporter systems.

6/1984 - 2/1989 Research FellowMerck Sharp & Dohme Research Laboratories (West Point, PA)RESPONSIBILITIES:Supervision of vascular biology laboratory to support drug-discovery programs in Cardiovascular (Hypertension, Heart Failure, Arrthymias, Stroke). Co-leader of discovery effort in calcium channel modulators and atrial natriuretic factor. Member of Merck/Astra discovery team which organized NDAs for felodipine (Splendil) and omeprazole (Prilosec).

3/1989 - 3/1994 Section Leader, Department of PharmacologyBoehringer Ingelheim Pharmaceuticals (Ridgefield, CT)RESPONSIBILITIES:Supervision of research group in Pharmacology Department supporting cardiovascular, respiratory and virology programs (Hypertension, Heart Failure, Acute Myocardial Infarction, Asthma, HIV) utilizing various models in rodents and non-human primates. Development of non-human primate models of hypertension (cynomolgus monkeys and marmosets) and myocardial ischemia-reperfusion injury (cynomolgus monkeys).Development and supervision of General Pharmacology assays (e.g., CNS, renal, cardiovascular and GI-function). Member of

- 4 -

Non-Nucleoside Reverse Transcriptase Inhibitor program/project team which identified/developed nevirapine (Viramune). Member of Angiotensin II blocker program/project team which identified/developed telmisartan (Mycardis).

3/1994 - 12/1997 Associate Director, Department of PharmacologyBoehringer Ingelheim Pharmaceuticals (Ridgefield, CT)RESPONSIBILITIES:Supervision of in vitro assays (e.g., cytokine [rodent and non-human primates] and electrophysiology assays) and in vivo models (pulmonary inflammation/dysfunction in cynomolgus monkeys, hypertension in non-human primates) for supporting drug discovery efforts in Cardiovascular, Pulmonary and Autoimmune therapeutic areas. Supervised transition of departmental research emphasis into the development of animal models of autoimmune disease (i.e., inflammatory bowel disease in HLAB27 transgenic rats, collagen-induced arthritis in mice, experimental autoimmune encephalomyelitis in mice, IDDM in BB rats). Completed pharmacology sections for INDs/NDAs and participated on project teams for compounds targeted for HIV (nevirapine, Viramune), Hypertension/Heart Failure (telmisartan, Mycardis) and Autoimmune Diseases (Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis, Psoriasis; anti-ICAM-1; Mobic).

12/1997 – 7/2003 DirectorDepartment of PharmacologyBoehringer Ingelheim Pharmaceuticals (Ridgefield, CT)RESPONSIBILITIES: Supervision of in vitro (e.g., cytokine assays, biomarker/surrogate marker assays) and in vivo laboratories (Proof of Principle-cytokine and Disease Relevant Models for Autoimmune Disease syndromes [e.g., RA, IBD, MS, IDDM], Respiratory [Asthma] and Cardiovascular Syndromes [Hypertension, Heart Failure, Peripheral Vascular Disease [porcine model for examining arteriogenesis approach in PAOD] ) to support drug discovery efforts. The animals models utilized rodents, pigs and non-human primates. Supervision of Animal Resources Group, General/Safety Pharmacology laboratories and Transgenics Facility (e.g., development of various Cre lines for Conditional Transgenic mice; development of Conventional Knock-Out mice for target validation studies).Participation as member of Discovery Management Team (with Directors of Biology and Medicinal Chemistry) which evaluated current research strategies/resourcing/progress as well as new targets (i.e., Target Identification) for Autoimmune and Cardiovascular programs. Participation and presentation in BI International Meetings (e.g., R&D Directors meetings; Therapeutic Area Director meetings) with focus on current and future research

- 5 -

strategies. Participation in the BI Clinical Experts Group for Immunology/Autoimmune and the CEG for Cardiovascular. Participation as member of In-Licensing Team for Immunology/Autoimmune and Cardiovascular programs. Selected as BI Discovery representative for working with the Boston Consulting Group to assess employee opinions of management and company work environment. Participated in joint BI-BCG strategy committee for improving productivity in Discovery departments.Development of strategic plans for preclinical Cardiovascular Department in Ridgefield. As a member of the Drug Discovery Committee, identified and helped develop the preclinical development work packages for the clinical candidate for HCV (entered into Phase I). Team member responsible for developing the preclinical strategy for the Micardis Phase IV program. In conjuction with Discovery Management Team developed strategic vision and strategy for new target identification/validation for Discovery Research in Immunology (emphasis on Autoimmune therapeutic areas).

8/2003 – 11/2005 Vice PresidentDepartment of PharmacologyScion Pharmaceuticals (Medford, MA)RESPONSIBILITIES:Supervision of in-house DMPK (e.g., in vitro metabolism, in vivo pharmacokinetics, brain penetration assays, bioanalytical assays, CYP assays, protein binding assays) and Pharmacology assays (e.g., models of chronic pain; analysis of heart rate) to support Discovery Programs of novel ion channel blockers for Neuropathic Pain and Atrial Fibrillation. Planning and supervision of work packages contracted with external laboratories for assessment of preclinical efficacy in advanced animal models (e.g., Bennett and Chung models of neuropathic pain; elevated heart rate in dogs and guinea pigs). Responsible for the planning of Preclinical Development plans, and construction of appropriate protocols, for Safety Pharmacology and Toxicology work packages. Managed external collaboration with toxicology CROs for IND-enabling studies. Participation as member of Senior Management Team in the strategic planning of Research/Development directions, evaluation of possible in-licensing candidates, the successful licensing-in of a Phase 2-ready compound, and presentations of research and development strategy to the Board of Directors, possible investor groups and corporate partners. Organizing external testing for in-house compounds in animal models of overactive bladder/interstitial cystitis.Development of Clinical Development Plan for Phase I and II for our internal modulator of CaV2.2 for Post-Operative and Neuropathic Pain. Organized Clinical Expert meetings to discuss

- 6 -

strategies for refining development plans. Responsible for completing Section 8 of IND (Filed 12/23/04). Paticipated and presented at pre-IND meeting with the FDA. Development of Clinical Development Plan for blocker of sarcolemma KATP channels for ventricular arrhythmias for possible in-licensing compound. Development of Clinical Development Plan for in-license compound for irritable bowel syndrome and male erectile dysfunction. Prepared briefing packet (essentially a Section 8) for pre-IND meeting with FDA for the in-license compound.

11/2005 to 10/2010 Vice President, PharmacologyVertex Pharmaceuticals IncCambridge, MARESPONSIBILITIESSupervision of in-house Pharmacology Department (approximately 50 scientists) as well as assays (e.g., human primary tumor xenograft models in mice, myelination/remyelination models in rodents, pulmonary function in rodents) to support Discovery Programs of novel therapeutics for Oncology, Neurodegenerative, Autoimmune and Infectious Diseases. Planning and supervision of work packages contracted with external laboratories for assessment of preclinical efficacy in advanced animal models (e.g., Collagen Induced Arthritis in mice). Responsible for the planning/executing of Safety Pharmacology work packages. Participation as member of the Global Planning Science Committee for the strategic planning and oversight of worldwide Drug Discovery Programs. Participation in committees for the evaluation of possible in-licensing candidates. Participated as scientific advisor for several collaborative programs with external sites (e.g., Harvard, Oregon Health Science University, McGowan Institute for Regenerative Medicine).

10/2010 to 11/2012 Vice President, Integrated BiologyVertex Pharmaceuticals IncCambridge, MARESPONSIBILITIESSupervision of in-house Integrated Biology Department (approximately 100 scientists) which includs Protein Sciences (e.g., cloning/expression/purification of proteins), Cell and Molecular Pharmacology, Virology, Bacteriology, Structural Biology and In Vivo Pharmacology. Continued, as stated above, to supervise assays/projects to support Discovery Programs of novel therapeutics for Oncology, Neurodegenerative, Autoimmune and Infectious Diseases. Supervision of Boston site Animal Facility.Continued, as stated above, participation as member of the Global Planning Science Committee for the strategic planning and oversight of worldwide Drug Discovery Programs, on committees

- 7 -

for the evaluation of possible in-licensing candidates and as scientific advisor for external collaborations.

11/2012 to 8/2015 Co-Site Head for Research; Vice President of Integrated BiologyVertex Pharmaceuticals IncCambridge/Boston, MARESPONSIBILITIESSupervision, as stated above, Department of Integrated Biology and took on responsibility/accountability for drug discovery research programs (co-site head) at the Boston facility. Continued supervision of Animal Facility and the planning for AAALAC accreditation.. Participation,, as stated above, on the GPSC for the strategic planning and oversight of all Vertex research programs, on committees for evaluating possible in-licensing candidates and as scientific advisor for external collaborations.

Invited Seminars, Lectures

10/1983: Symposium of Topics in Preclinical Cardiovascular New Drug Discovery, Saddle Brook, NJ." Modulators of Intracellular Calcium."

8/1984: Vascular Neuroeffector Mechanisms (Satellite Symposium of the 9th International Congress of Pharmacology) Paris, France."Regional Vascular Effects of Atrial Natriuretic Factor."

11/1984: Chairman and speaker, Symposium on "Atrial Natriuretic Factor: Emergence of a New Cardiovascular Regulatory System," Philadelphia Physiological Society.

4/1985: Symposium on "Membrane ATPase Function in Vascular Muscles in Hypertension," FASEB. "Vascular Effects of Atrial Natriuretic Factor."

8/1985: Symposium on "Atrial Natriuretic Factor," American Society of Pharmacology & Experimental Therapeutics."Mechanism of Vasorelaxation of ANF."

9/1985: Symposium of Topics in Preclinical Cardiovascular New Drug Discovery, North Brunswick, NJ."Altered Endothelium-Dependent Responses in Hypertension."

3/1986: First International Symposium on Atrial Natriuretic Factor, Clinical Research Institute, Montreal, Canada. "Species and Regional Vascular Differences in the Vasorelaxant Effects of Atrial Natriuretic Factor."

- 8 -

4/1986: Symposium on Neurohumoral Control of Blood Vessel Tone, Springfield, IL. "The Vasodilator Effects of Atrial Natriuretic Factor."

7/1986: Symposium on Mechanisms of Vasodilation, Rochester, MN. "Species Differences in the Vasorelaxant Effects of Atrial Natriuretic Factor."

7/1986: Symposium on Blood Pressure Regulating Systems, Whistler, B.C., Canada."The Actions of Atrial Natriuretic Factor in the Vascular Wall."

10/1986: Symposium on Endothelium and Vascular Functions, APS Fall Meeting, New Orleans, LA. "Endothelium-Derived Vasoactive Factor(s) in Hypertension."

5/1987: Distinguished Scientists Seminar Program, University of South Alabama, Mobile AL. "Cardiovascular and Renal Effects of Atrial Natriuretic Peptides."

1/1988: 2nd International Symposium on Resistance Arteries, Burlington, VT. "Regional Differences in the Ability of Atrial Natriuretic Peptideto Enhance Vascular Permeability."

8/1988: FASEB Summer Conference, Discussion Leader on Hypertension Session for "Endothelium and Cardiovascular Function."

1/1989: Invited speaker for 2nd Symposium on "Molecular and Cellular Aspects of Vascular Smooth Muscle in Health and Disease," held jointly as a US/Japan cooperative Science Symposium.

4/1989: Invited speaker for 197th American Chemical Society National Meeting, Symposium on "Potassium Channel Openers: New Biological Probes." Title of presentation: "Vasodilators and Potassium Channels."

11/1989 Presentation at the Symposium on Myocardial Reperfusion Injury-Novel Therapeutic Strategies Symposium Title, "Evaluation of an anti-CD18 monoclonal antibody in a primate model of myocardial reperfusion injury."

6/1990: Presentation at the NATO Symposium on "Vascular Endothelium: Physiological Basis of Clinical Problems." Title of presentation, "Blockade of CD18-dependent neutrophil adhesion limits myocardial infarct size following coronary artery occlusion in cynomolgus monkeys.

- 9 -

1/1991: Invited speaker for Philadelphia Physiological Society Symposium on "Reperfusion Injury." Title of presentation: "Role of Cell Adhesion Molecules in Reperfusion Injury."

2/1992: Presentation at the Gordon Conference on Angiotensins. Title of abstract, "Hypotensive effects of losartan (DuP 753) and its metabolite, EXP3174, in conscious, sodium-depleted cynomolgus monkeys.

5/1992: Invited speaker for the A.N. Richards Symposium on Reperfusion Injury. Title of presentation: "Pans in Primate Models of Ischemia."

6/1992: Invited speaker for the IBC conference on New Cardiovascular Drugs and Other Therapeutic Advancements. Title of presentation: "Antibodies of Glycoproteins Instrumental in Trafficking."

2/1994: Invited speaker for the Third US/JAPAN Symposium on Cellular and Molecular Aspects of Vascular Smooth Muscle Function.

6/2001 Invited speaker for the 2nd European Journal of Pharmacology Spring Meeting, “Neuropathic Pain and Inflammation”, Zeist, The Netherlands. Title of presentation: “The role of leukocyte function-associated antigen-1 in animal models of inflammation.”

3/2003 Invited speaker for IBC meeting on Pharmacology in Drug Development held in Boston. Title of presentation: “Models of Altered Immune Function”.

2/2012 Chairperson, MMTC meeting on cancer stem cells, San Francisco, CA.

6/2014 Invited Panelist, BIO 2014, session entitled: Encounters in the Third Dimension: Improving the Clinical Predictability of Preclinical Models for Drug Discovery and Disease Modeling.

Society Memberships and Editorial Boards

American Physiological Society, 1981-1996

Fellow, Council for High Blood Pressure, American Heart Association, 1986-present

American Society of Pharmacology & Experimental Therapeutics, 1988-present

Editorial Board, Journal of Pharmacology & Experimental Therapeutics, 1988-present

- 10 -

Associate Editor, Journal of Pharmacology & Experimental Therapeutics, 2005-present

Editorial Board, European Journal of Pharmacology, 1990-2002; Editorial Board Consultant, 2002-2004

Editorial Board, Biochemical Pharmacology, 2003-present

Member, ASPET Committee on Industrial-Academic Relations, 1989-1997

Coordinator of ASPET Speaker's Program, 1993-1997

Board of Directors, Safety Pharmacology Society, 2000-2001

Nomination Committee, Safety Pharmacology Society, 2001-2001

Elected Counselor to ASPET Cardiovascular Division Executive Committee, 2001 to 2003

Scientific Advisory Board, Bender MedSystems, 2002-2003

- 11 -

BIBLIOGRAPHYOF

RAYMOND J. WINQUIST

Completed Publications in Scientific Journals

1. Winquist, R.J. and Bevan, J.A.: Development of intrinsic muscle tone in the rabbit facial vein. Proc. West. Pharmacol. Soc. 20 149-152, 1977.

2. Winquist, R.J. and Bevan, J.A.:The effect of surgical sympathetic denervation upon the development of intrinsic myogenic tone and the ß-adrenergic receptor-mediated responses of the rabbit facial vein. J. Pharmacol. Exp. Ther. 211: 1-6, 1979.

3. Winquist, R.J. and Bevan, J.A.:Temperature sensitivity of tone in the rabbit facial vein: Myogenic mechanism for cranial thermoregulation? Science 207: 1001-1003, 1980.

4. Winquist, R.J. and Bevan, J.A.: In vitro model of maintained myogenic vascular tone. Blood Vessels 18: 134-138, 1981.

5. Winquist, R.J. and Bevan, J.A.: Relative location of a- and b-adrenergic receptors to sympathetic sites of release in the rabbit facial vein. Circ. Res. 49: 486-492, 1981.

6. Winquist, R.J., Webb, R.C. and Bohr, D.F.: Calcium antagonism is no rose. Fed. Proc. 40: 2852-2854, 1981.

7. Webb, R.C., Winquist, R.J., Victery, W. and Vander, A.J.: Acute and chronic effects of lead treatment in vascular reactivity in rats. Am. J. Physiol. 241: H211-H216, 1981.

8. Bevan, J.A., Bevan, R.D., Florence, V.M., McCalden, T.A., Pearce, W.J. Rowan, R.A. and Winquist, R.J.: Specialization in cerebral and extracerebral neurovascular mechanisms. Fed. Proc. 40: 2301-2305, 1981.

9. Winquist, R.J., Webb, R.C., and Bohr, D.F.:Vascular smooth muscle in hypertension. Fed. Proc. 41: 2387-2393, 1982.

10. Winquist, R.J. and Bohr, D.F.:

- 12 -

Characterization of the rat basilar artery in vitro. Experientia 38: 1187-1188, 1982.

11. Winquist, R.J. and Bohr, D.F.: Relaxation to transmural nerve stimulation and exogenously added norepinephrine in porcine cerebral vessels. A study utilizing cerebrovascular intrinsic tone. Cir. Res. 51: 769-776, 1982.

12. Winquist, R.J. and Bohr, D.F.: Structural and functional changes in cerebral arteries from spontaneously hypertensive rats.Hypertension 5: 292-297, 1983.

13. Anderson, H.L. III, Winquist, R.J. and Bohr, D.F.: Mechanism of canine coronary artery relaxation by monensin. Circ. Res. 53: 168-175, 1983.

14. Winquist, R.J. and Backlund, E.B.: Calcium translocation through channels resistant to calcium entry blockers in a rabbit vein. Am. J. Physiol. 245: H1024-H1030, 1983.

15. Winquist, R.J.: Modulators of intracellular calcium. Drug Dev. Res. 4: 241-256, 1984.

16. Winquist, R.J., Siegl, P.K.S., Baskin, E.P., Bohn, D.L., Morgan, G. and Wallace, A.A.: The calcium entry blocker activity of cyproheptadine in isolated cardiovascular preparations. J. Pharmacol. Exp. Ther. 230: 103-109, 1984.

17. Winquist, R.J., Faison, E.P. and Nutt, R.F.: Vasodilator profile of synthetic atrial natriuretic factor. Eur. J. Pharmacol. 102: 169-173, 1984.

18. Napier, M.A., Vandlen, R.L., Albers-Schonberg, G., Nutt, R.F., Brady, S., Lyle, T., Winquist, R. and Faison, E.: Specific membrane receptors for atrial natriuretic factor in renal and vascular tissues. Proc. Natl. Acad. Sci. USA, 81: 5946-5950, 1984.

19. Winquist, R.J., Bunting, P.B., Baskin, E.P. and Wallace, A.A.: Decreased endothelium-dependent relaxation in New Zealand genetic hypertensive rats. J. Hypertension, 2: 541- 545, 1984.

20. Winquist, R.J., Faison, E.P., Waldman, S.A., Schwartz, K., Murad, F. and Rapoport, R.M.: Atrial natriuretic factor elicits an endothelium- independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle.

- 13 -

Proc. Natl. Acad. Sci. USA, 81: 7661-7664, 1984.

21. Winquist, R.J., Faison, E.P., Baskin, E.P., Bunting, P.B. and Callahan, L.T.: Characterization of synthetic atrial natriuretic factor: vasodilator profile and decreased vascular sensitivity in hypertensive rats. J. Hypertension, 2 (suppl. 3): 325-327, 1984.

22. Winquist, R.J., Napier, M.A., Vandlen, R.L., Arcuri, K., Keegan, M.E., Faison, E.P. and Baskin, E.P.: Pharmacology and receptor binding of atrial natriuretic factor in vascular smooth muscle. Clin. Exp. Hypertension, A7: 869-886, 1985.

23. Faison, E.P., Siegl, P.K.S., Morgan, G. and Winquist, R.J.: Regional vasorelaxant selectivity of atrial natriuretic factor in isolated rabbit vessels. Life Sci. 37: 1073-1079, 1985.

24. Winquist, R.J.: The relaxant effects of atrial natriuretic factor on vascular smooth muscle. Life Sci. 37: 1081-1087, 1985.

25. Rapoport, R.M., Waldman, S.A., Schwartz, K., Winquist, R.J. and Murad, F.: Effects of atrial natriuretic factor, sodium nitroprusside, and acetylcholine on cyclic GMP and relaxation in rat aorta. Eur. J. Pharmacol. 115: 219-229, 1985.

26. Winquist, R.J., Bunting, P.B. and Schofield, T.L. Blockade of endothelium-dependent relaxation by the amiloride analog dicholorobenzamil: Possible role of Na+/Ca++ exchange in the release of endothelium-derived relaxant factor. J. Pharmacol. Exp. Ther. 235: 644-650, 1985.

27. Rapoport, R.M., Winquist, R.J., Baskin, E.P., Faison, E.P., Waldman, S.A. and Murad, F.: Effects of atriopeptins on relaxation and cyclic GMP levels in rat and rabbit aortas. Eur. J. Pharmacol. 120: 123-126, 1986.

28. Winquist, R.J.: Altered vasodilator and endothelium-dependent responses in hypertension. Drug Dev. Res. 7: 311-318, 1986.

29. Winquist, R.J.: Possible mechanisms underlying the vasorelaxant response to atrial natriuretic factor. Fed. Proc. 45: 2371-2375, 1986.

30. Baldwin, J.J., Claremon, D.A., Lumma, P.K., McClure, D.E., Rosenthal, S.A., Winquist, R.J., Faison, E.P., Kaczorowski, G.J., Trumble, M.J. and Smith, G.M.:Diethyl 3,6-dihydro-2,4- dimethyl-2,6-methano-1,3-benzothia- thiazocine-5,11- dicarboxylates as calcium entry antagonists: new conformationally restrained analogs of

- 14 -

Hantzsch 1,4- dihydropyridines related to nitrendipine as probes for receptor site conformation. J. Med. Chem. 30: 690-695, 1987.

31. Winquist, R.J.: Modulation of vascular tone by atrial natriuretic factor. Blood Vessels 24: 128-131, 1987.

32. Winquist, R.J.: Pharmacological effects of atrial natriuretic peptide. Endocrinol. Metab. Clinics of North Am. 16: 163- 182, 1987.

33. Vlasuk, G.P., Babilon, R., Nutt, R.F., Ciccarone, T.M. and Winquist, R.J.: The actions of atrial natriuretic factor on the vascular wall. Can. J. Physiol. Pharmacol. 65: 1684- 1689, 1987.

34. Hwang, S.-B., Chang, M.N., Garcia, M.L., Han, Q.Q., Huang, L., King, V.F., Kaczorowski, G.J. and Winquist, R.J.: L-652-469 - A dual receptor antagonist of platelet activating factor and dihydropyridine from Tussilago farfara L. Eur. J. Pharmacol. 141 269-281, 1987.

35. Winquist, R.J., Baskin, E.P. and Vlasuk, G.P.: Synthetic tumor-derived human hypercalcemic factor exhibits parathyroid hormone-like vasorelaxation in renal arteries. Biochem. Biophys. Res. Comm. 149: 227-232, 1987.

36. Chicchi, G.G., Gimenez-Gallego, G., Ber, E., Garcia, M.L., Winquist, R. and Cascieri, M.A.: Purification and characterization of a unique, potent inhibitor of apamin binding from Leiurus quinquestriatus hebraeus venom. J. Biol. Chem. 263: 10192-10197, 1988.

37. Caulfield, M.P., Levy, J.J., McKee, R.L., Goldman, M.E., DeHaven, P.A., Reagan, J.E. Heaney, L., Nutt, R.F., Winquist, R.J., Russell, J., Sherwood, L.M., and Rosenblatt, M.: Avian (chicken) parathyroid hormone: synthesis and comparative biological evaluation of the 1-34 fragment. Endocrinology, 123, 2949-2951, 1988.

38. Winquist, R.J., Heaney, L.A., Wallace, A.A., Baskin, E.P., Stein, R.B., Garcia, M.L., and Kaczorowski, G.: Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle. J. Pharmacol. Exp. Ther., 248: 149-156, 1989.

39. Winquist, R.J., Bunting, P.B., Garsky, V.M., Lumma, P.K. and Schofield, T.L.: Prominent depressor response to endothelin in spontaneously hypertensive rats. European J. Pharmacol., 163: 199-203, 1989.

40. Winquist, R.J., Scott, A.L. and Vlasuk, G.P.: Enhanced release of atrial natriuretic peptide by endothelin in atria from hypertensive rats. Hypertension 14: 111-114, 1989.

- 15 -

41. Schaffer, L.M., Schorn, T.W., Winquist, R.J., Strouse, J.F. and Siegl, P.K.S.: Acute hypotensive responses to peptide inhibitors of renin in conscious monkeys: an effect on blood pressure independent of plasma renin inhibition. J. Hypertension 8: 251-259, 1990.

42. Garcia, M.L., King, V.F., Shevell, J.L., Slaughter, R.S., Suarez-Kurtz, G., Winquist, R.J. and Kaczorowski, G.J.: Amiloride analogs are potent inhibitors of L-type calcium channels. J. Biol. Chem., 265: 3763-3771, 1990.

43. Winquist, R.J. and Hintze, T.: Mechanisms of ANF-induced vasodilation. Pharmac. Ther. 48: 417-426, 1990.

44. Li, T., Croce, K. and Winquist, R.J.:Regional differences in the effects of septic shock on vascular reactivity in the rabbit.J. Pharmacol. Exp. Ther., 261: 959-963, 1992.

45. Li. T., Croce, K., and Winquist, R.J.: Vasoconstrictor and vasodilator effects of serotonin in the isolated, perfused rabbit kidney. J. Pharmacol. Exp. Ther., 263: 928-932, 1992.

46. Baskin, E.P., Serik, C.M., Wallace, A.A., Jurkiewicz, N.K., Winquist, R.J. and Lynch, J.J.: Vascular effects of class III antiarrhythmic agents. Drug Dev. Res. 26: 481-488, 1992.

47. Madwed, J.B. and Winquist, R.J.: Effects of losartan (DuP753) and enalaprilat on the mean arterial pressure response to phenylephrine.J. Hypertension, 12: 159-162, 1994.

48. Panzenbeck, M.J., Harrison, P.C., Madwed, J.B., McFarland, M.L., Winquist, R.J., Frei, P.P., Weldon, S.W. and Desai, S.N.: Sodium depletion in conscious cynomolgus monkeys attenuates baroreflex sensitivity independently of prostaglandins.Amer. J. Physiol (Heart), 266: H2430-H2435, 1994.

49. Panzenbeck, M.J., Loughnan, C.L., Madwed, J.B., Winquist, R.J. and Fogal, S.E.: Captopril-induced hypotension is inhibited by the bradykinin blocker HOE-140 in Na+-depleted marmosets. Amer. J. Physiol., 269: H1221-H1228, 1995.

50. Weldon, S.M., Winquist, R.J. and Madwed, J.B.: Differential effects of L-NAME on blood pressure and heart rate responses to acetylcholine and bradykinin in cynomolgus primates.J. Pharmacol. and Exp. Ther., 272: 126-133, 1995.

51. Winquist, R.J. and Kerr, S.: Cerebral ischemia-reperfusion injury and adhesion.Neurology; 49: (Suppl 4):S23-S26, 1997.

- 16 -

52. Pairet, M., Diederen, W., Guth, B., Kanai, K., Mauz, A., Pieper, M., van Ryn, J., Schierok, H., Walland, A. and Winquist, R.: General pharmacology studies in the pharmaceutical industry: Example of a basic program. Drug Dev. Res., 42: 57-62, 1997.

53. Kerr, S.W., Yu, R., Stearns, C.D., Haynes, N.A. and Winquist, R.J.: Characterization of the polymorphonuclear leukocyte-induced vasoconstriction in isolated human umbilical arteries.J. Pharmacol. and Exp. Ther., 287: 640-647, 1998.

54. Kerr, S.W., Wolyniec, W.W., Filipovic, Z., Nodop, S.G., Braza, F., Winquist, R.J. and Noonan, T.C.: Repeated measurement of intestinal permeability as an assessment of colitis severity in HLA-B27 transgenic rats. J. Pharmacol. and Exp. Ther., 291: 903-910, 1999.

55. Simoneau, B., Lavallee, P., Anderson, P.C., Bailey, M., Bantle, G., Berthiaume, S., Chabot, C., Fazal, G., Halmos, T., Ogilvie, W.W., Poupart, M.A., Thavonekham, B., Xin, Z., Thibeault, D., Bolger, G., Panzenbeck, M., Winquist, R.J. and Jung, G.L.: Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy. Bioorganics & Med. Chem. 7: 489-508, 1999.

56. Winquist, R.J., Desai, S., Fogal, S., Haynes, N.A., Nabozny, G.H., Reilly, P.L., Souza, D., and Panzenbeck, M.: The role of leukocyte function-associated antigen-1 in animal models of inflammation. Eur. J. Pharmacol., 429: 297-302, 2001.

57. Gribkoff, V.K. and Winquist, R.J.: Novel non-ligand gated ion channel approaches to the treatment of stroke and cerebrovascular disease. Invited Review, Expert Opinion on Investigational Drugs, 14: 579-592, 2005.

58. Winquist,R.J., Pan, J.Q. and Gribkoff, V.K.: Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Invited Review, Biochemical Pharmacol., 70: 489-499, 2005.

59. Winquist, R.J., Kwong, A., Ramachandran R. and Jain, J.: The complex etiology of multiple sclerosis. Biochemical Pharmacol., 74: 1321-1329, 2007.

60. Winquist, R.J., Boucher, D.M., Wood, M. and Furey, B.F.: Targeting cancer stem cells for more effective therapies: Taking out cancer’s locomotive engine. Biochemical Pharmacol., 78: 326-334, 2009.

61. Winquist, R.J. and Boucher, D.M.: Factors influencing development of new therapeutics for oncology. Curr. Opin. Pharmacol., 10: 353-355, 2010.

62. Winquist, R.J., Furey, B.F. and Boucher, D.M.: Cancer stem cells as the relevant biomass for drug discovery. Curr. Opin. Pharmacol., 10: 385-390, 2010.

- 17 -

63: Johnson, M.A. and Winquist, R.J.: Island biogeography effects on microbial evolution may contribute to Crohn’s disease. Biochemical Pharmacol, 82: 1801-1806, 2011.

64. Winquist, R.J., Mullane, K. and Williams, M.: The fall and rise of pharmacology—(re-)defining the discipline? Biochemical Pharmacol, 87: 4-24, 2014.

65. Mullane, K., Winquist, R.J. and Williams, M.: Translational paradigms in pharmacology and drug discovery. Biochemical Pharmacol, 87: 189-210, 2014

66. Mullane, K., Winquist, R. and Williams, M.: Pharmacology in the 21st century biomedical research. Preface. Biochemical Pharmacol, 87: 1-3, 2014.

67. Kenakin, T., Bylund, D.B., Toews, M.L., Mullane, K., Winquist, R.J. and Williams, M.: Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century. Biochemical Pharmacol, 87: 64-77, 2014.

68. Winquist, R.J., Hall, A.B., Eustace, B.K. and Furey, B.F.: Evaluating the immortal strand hypothesis in cancer stem cells: symmetric/self-renewal as the relevant surrogate marker of tumorigenicity. Biochemical Pharmacol, 91: 129-134, 2014.

69. Farmer, L.J., Ledeboer, M.W., Hoock, T. et al (43 authors): Discovery of VX-509 (Decernotinib): A potent and selective Janus Kinase 3 inhibitor for the treatment of autoimmune diseases. J. Med. Chem. in the press, 2015.

Chapters in Books

1. Bevan, J.A., Pegram, B.L., Prehn, J.L. and Winquist, R.J.: Beta-adrenergic receptor-mediated vasodilation. In: Mechanisms of Vasodilation, P. Vanhoutte and I. Leusen, Eds., pp. 258-265, S. Karger, Basel, 1978.

2. Winquist, R.J., Webb, R.C. and Bohr, D.F.: Calcium other ions and the contractile process. In: The Coronary Artery, S. Kalsner, Ed., pp. 91-117, Croom Helm Ltd., London, 1982.

3. Bevan, J.A., Bevan, R.D., Hwa, J.J., Owen, M.P., Tayo, F.M. and Winquist, R.J.: Calcium, extrinsic and intrinisic (myogenic) vascular tone. In: Calcium Modulators, T. Godfraind, A. Albertini and R. Paoletti, Eds., pp. 125-132, Elsevier, Holland, 1982.

4. Winquist, R.J., Rowan, R.A. and Bevan, J.A.: The facial vein as a temperature sensitive sphincter involved in cerebral thermoregulation. In: The Cerebral Veins, L.M. Auer and F. Loew, Eds., pp. 187-191, Springer-Verlag, Austria, 1983.

5. Bevan, J.A., Hwa, J.J., Owen, M.P. and Winquist, R.J.: Calcium and myogenic or stretch-dependent vascular tone. In: Calcium in Biological Systems, R. Rubin, J.W. Putney, Jr. and G. Weiss, eds., pp. 391-398, Plenum Publishing Corporation, New York, 1984.

6. Nutt, R.F., Brady, S.F., Lyle, T.A., Dylion-Colton, C., Paleveda, W.J., Ciccarone, T.M., Blaine, E.H., Winquist, R.J., Bennett, C.D., Hirschmann, R. and Veber, D.F.: Synthesis

- 18 -

of peptides with atrial natriuretic factor sequence. In: Peptides 1984, Proceedings of the 8th European Peptide Symposium. U. Ragnarsson, ed., Almqvist and Wiksell, Uppsala, 1984 p. 513-516.

7. Winquist, R.J., Faison, E.P., Napier, M., Vandlen, R., Waldman, S., Murad, F. and Rapoport, R.: The effects of atrial natriuretic factor on vascular smooth muscle. In: Vascular Neuroeffector Mechanisms, J.A. Bevan, et al., eds., Elsevier, Holland, p. 349-353, 1985.

8. Nutt, R.F., Brady, S.F., Lyle, T.A., Ciccarone, T.M., Paleveda, W.J., Dylion Colton, C., Veber, D.F. and Winquist, R.J.: Synthesis of atrial natriuretic factor and highly active analogs. In: Protides of the Biological Fluids, Vol. 34, Pergamon Press, p. 55-58, 1986.

9. Winquist, R.J.: Endothelium-dependent relaxation in hypertensive blood vessels. In: Endothelium-Derived Relaxing and Contracting Factors, P.M. Vanhoutte, ed., The Humana Press, Inc., New Jersey, p. 473-494, 1988.

10. Winquist, R.J., Baskin, E., Faison, E. and Gould, R.: Regional differences in atrial natriuretic peptide (ANP)-induced vascular permeability in rats. In: Resistance Arteries. W. Halpern, J. Brayden, M. McLaughlin, G. Osol, B. Pegram and K. MacKey, eds. Perinatology Press, New York (p. 435-441, 1988).

11. Winquist, R.J., Baskin, E.P., Faison, E.P. and Wallace, A.A.: Species and regional vascular heterogeneity to atrial natriuretic factor. In: Mechanisms of Vasodilation, P.M. Vanhoutte, ed., Raven Press, pp 119-122, 1988.

12. Winquist, R.J., Vlasuk, G., Smith, R., Gomez, H. and Irvin, J.: Atrial natriuretic peptides. In: Proteins and Peptides as Drugs, P.I. Nadler, ed., Marcel Dekker, 1989.

13. Winquist, R.J. and Vlasuk, G.: Receptors for atrial natriuretic factor. In: Membranes and Receptors, Volume 3 of Comprehensive Medicinal Chemistry, J.C. Emmett, ed., Pergamon Press, 1989, pp 981-1000, 1990.

14. Nutt, R.F., Ciccarone, T.M., Brady, S.F., Dylion Colton, C., Paleveda, J., Lyle, T.A., Williams, T.M., Veber, D.F., Wallace, A. and Winquist, R.J.: Structure activity studies of atrial natriuretic factor. In: Peptides: Structure and Function, Proceedings of the 10th American Peptide Symposium, 1989.

15. Nutt, R.F., Ciccarone, T.M., Brady, S.F., Dylion Colton, C., Williams, T.M., Winquist, R.J. and Veber, D.F.: ANF analogs designed to exhibit increased metabolic stability. In: Peptide Chemistry 1987, Proceedings of Japanese Symposium on Peptide Chemistry, 1990.

16. Nutt, R.F., Brady, S.F., Lyle, T.A., Ciccarone, T.M., Colton, C.D., Paleveda, W.J. Williams, T.M., Smith, G.M., Winquist, R.J. and Veber, D.F.: Development of a bioactive model of atrial natriuretic factor. In: Synthetic Peptides: Approaches to Biological Problems. Proceedings of UCLA Symposium, 1990.

- 19 -

17. Weiss, G.B., Winquist, R.J. and Silver, P.J.: Vascular Smooth Muscle and Vasodilators. In: Cardiovascular Pharmacology, 3rd Edition, M.J. Antonaccio, ed., Raven Press, pp 75-105, 1990.

18. Winquist, R.J., Bunting, P.B., Lumma, P.K., Garsky, V.M., Scott, A.L. and Vlasuk, G.P.: The depressor response to endothelin in normotensive and hypertensive rats. In: Endothelium-Derived Vasoactive Factors, Proceedings of the 1st International Symposium, G.M. Rubanyi and P.M. Vanhoutte, eds., pp 104-109, 1990.

19. Winquist, R.J.: Inhibitors of Atrial Natriuretic Factor Degradation. In: Receptor Data for Biological Experiments, Ellis Horwood, London, pp 87-91, 1991.

20. Rothlein, R., Barton, R.W. and Winquist, R.: The role of intercellular adhesion molecule-1 (ICAM-1) in the inflammatory response. In: Cellular and Molecular Mechanisms of Inflammation, Academic Press, San Diego, pp. 171-180, 1991.

21. Winquist, R.J. and Weldon, S.W.: Analysis of endothelin-1, 2 and 3 on microvascular blood flow and permeability in rabbit skin. In: Resistance Arteries, Structure and Function, Elsevier, Amsterdam, pp 252-254, 1991.

22. Winquist, R.J.: Inhibitors of Atrial Natriuretic Factor Degradation. In: Receptor Data for Biological Experiments, Ellis Horwood, New York, pp. 87-91, 1991.

Selected Abstracts

1. Fischer, J.R., Winquist, R.J., Cho, A.K., Lindeke, B. and Hallstrom, G.: The interaction of some a-substituted phenylethylamines with catecholamine systems. Fed. Proc. 36: 381, 1977.

2. Bevan, J.A., Bevan, R.D., Pegram, B.L., Prehn, J.L. and Winquist, R.J.: Beta-adrenergic receptor-mediated vasodilation in a blood vessel with intrinsic muscle tone. Blood Vessels 14: 258, 1977.

3. Winquist, R.J. and Bevan, J.A.: The effect of sympathetic denervation upon developed tone and adrenergic responses of the rabbit facial vein. Blood Vessels 16: 224, 1979.

*4. Winquist, R.J. and Bevan, J.A.: The effects of adrenergic denervation upon the a-and-b-

receptor-mediated responses of the rabbit facial vein. Pharmacologist 20: 154, 1978.

5. Winquist, R.J.: Small changes in the ambient temperature affect the level of myogenic tone of the rabbit facial vein. Fed. Proc. 38: 367, 1979.

6. Winquist, R.J. and Bevan, J.A.: Relaxant properties of vasodilators on the myogenic tone of the rabbit facial vein. Blood Vessels 17: 169, 1980.

- 20 -

7. Winquist, R.J. and Bevan, J.A.: Verapamil potentiation of calcium-sensitive vascular myogenic tone. Fed. Proc. 38: 833, 1980.

8. Bevan, J.A., Bevan, R.D., Florence, V.M., McCalden, T.A. and Winquist, R.J.: In vitro studies of specialized cerebral neurovascular mechanisms. Abstract for the 28th International Congress of Physiological Sciences, Budapest, 1980.

9. Winquist, R.J., and Bohr, D.F.: Development of myogenic tone and neurogenic relaxation of the porcine basilar artery. Physiologist 23: 60, 1980.

10. Winquist, R.J., Webb, R.C. and Bohr, D.F.: Calcium-induced relaxation in vascular smooth muscle from control and DOCA-hypertensive pigs. Fed. Proc. 40: 410, 1981.

11. Anderson, H.L., Winquist, R.J. and Bohr, D.F.: Relaxant effects of monesin on the isolated canine artery. Physiologist 24: 36, 1981.

12. Winquist R.J. and Backlund, E.P. Verapamil- and diltiazem-resistant calcium channels in *the rabbit facial vein. Abstract for annual meeting of Southeastern Pharmacology Society, 1981.

13. Winquist, R.J. and Morris, A.A.: The effects of verapamil and diltiazem on drug induced and myogenic tone in feline cerebral, coronary and renal arteries. Fed. Proc. 41: 1632, 1982.

14. Winquist, R.J. and Bohr, D.F.: Structural and functional changes in cerebral arteries from spontaneously hypertensive rats. Fed. Proc. 42: 1262, 1983.

15. Baskin, E.P., Morgan, G. Siegl, P.K.S., Wallace, A.A. and Winquist, R.J.: Comparison of cyproheptadine and verapamil as calcium entry blockers in isolated vascular and cardiac preparations. Fed. Proc. 42: 1345, 1983.

16. Wallace, A.A. and Winquist, R.J.: Analysis of the effects of calcium entry blockers on a1- and a2-agonist contractions in isolated rat arteries. Fed. Proc. 42: 618, 1983.

17. Winquist, R.J. and Baskin, E.P.: Receptor-, voltage- and distention-operated calcium channels in vascular smooth muscle.: Bull. of the Phila. Physiol. Soc. 2: 14, 1983.

18. Baskin, E.P. and Winquist, R.J.: ß-receptor-mediated vasodilator activity of several ß-blockers in isolated veins. Pharmacologist 25: 136, 1983.

19. Winquist, R.J.: Characterization of synthetic atrial natriuretic factor: Vasodilator profile and decreased vascular sensitivity of hypertensive rats. 10th Scientific Meeting of the International Society of Hypertension, Interlaken, Switzerland, 1984. abstract #160.

20. Faison, E.P. and Winquist, R.J. Regional vasodilator selectivity of synthetic atrial natriuretic factor. J. Clin. Pharmacol. 24: 419, 1984.

- 21 -

21. Winquist, R.J. and Bunting, P.B.: The dependence on extracellular calcium for the release of endothelial relaxation factor in rat aorta: Role of Na+/Ca++ exchange? IUPHAR 9th International Congress of Pharmacology, London, 1984, abstract #412.

22. Napier, M.A., Keegan, M., Faison, E., Winquist, R., Arcuri, K. and Vandlen, R.: High affinity ANF receptors in rabbit vascular tissues. Fed. Proc. 44: 1237, 1985.

23. Faison, E.P. and Winquist, R.J. Synthetic atrial natriuretic factor: in vivo vasodilator selectivity in conscious hypertensive and normotensive rats. Clin. Res. 33: A761, 1985.

24. Baskin, E., Faison, E., Wallace, A., Schofield, T. and Winquist, R.: Species differences in the vasorelaxation relative potency of atrial peptides. J. Clin. Pharmacol. 25: 467, 1985.

25. Nutt, R.F., Brady, S.F., Ciccarone, T.M., Lyle, T.A., Paleveda, W.J., Dylion-Colton, C., Veber, D.F. and Winquist, R.J. Synthesis of ANF and analogs. Abstract, 1st World Congress on Biologically Active Atrial Peptides. May 31 - June 1, 1986, p. 118A.

26. Jacobs, J.W., Condra, C., Winquist, R.J., Banskota, N. and King, G.L. Heterogeneity of human ANF receptors: implications for biological potency of atrial natriuretic factors. Clin. Res. 34: 310A, 1986.

27. Winquist, R.J. and Baskin, E.P. Ca dependence of myogenic tone in the rabbit facial vein: possible role of Na/Ca exchange in Ca-induced relaxation. Proc. Intl. Union Physiol. Sci 16: 443, 1986.

28. Baskin, E.P. and Winquist, R.J. Effect of age on the relaxation of renal arteries from SHR and WKY rats. Pharmacologist 28: 161, 1986.

29. Leidy, E.M. and Winquist, R.J. Effect of synthetic atrial natriuretic factor (sANF) upon glomerular filtration rate (GRF) in anesthetized rats. Pharmacologist 28: 104, 1986.

30. Wallace, A., Vlasuk, G., Faison, E. and Winquist, R. Vasodilation of renal arteries by bovine parathyroid hormone. Pharmacologist 28: 161, 1986.

31. Winquist, R., Wallace, A. and Faison, E. The effects of nitroglycerin-induced tolerance on the relaxation of endothelium-independent and dependent vasodilators in rabbit aortic segments. Fed. Proc. 46: 386, 1987.

32. Leidy, E.M., Bondi, J., Loper, A., Mazack, E.K., and Winquist, R. Nasal and subcutaneous administration of synthetic atrial natriuretic factor (sANF) to anesthetized rats. Fed. Proc. 46: 1128, 1987.

33. Winquist, R., Baskin, E., Faison, E. and Gould, R. Regional differences in atrial natriuretic peptide (ANP)- induced vascular permeability in rats. Blood Vessels 25: 52, 1988.

- 22 -

34. Schaffer, L.W., Winquist, R.J. and Siegl, P.K.S. Hypotensive effect of inhibition of renin and converting enzyme in normotensive African Green monkeys. FASEB. J. 2: A605, 1988.

35. Winquist, R.J., Heaney, L.A. and Baskin, E.P. Blockade of the relaxation to BRL 34915 and minoxidil by glyburide in isolated rat portal veins. FASEB J. 2: A786, 1988.

36. Roy-Contancin, L., Velasco, G., Katz, G., Winquist, R., Garcia, M., Kaczorowski, G. and Reuben, J.P. Regulation of high conductance Ca-activated K+ channels (PKCa) by GMP. Biophysical J. 1989.

37. Schaffer, L.W., Emmert, S., Winquist, R., Sweet, C., Greenlee, W., Chakravarty, P., and Siegl, P. Evidence for a renin-independent hypotensive mechanism for renin inhibitor, L-157,119, in rats. FASEB J.3: A994, 1989.

38. Winquist, R.J., Baskin, E.P. and Heaney, L.A. Glyburide blocks the depressor response to BRL 34915 (cromakalin) and pinacidil in anesthetized rats. FASEB J. 3: A1196, 1989.

39. Argenbright, L., Winquist, R., Letts, L.G. and Rothlein, R.: Monoclonal antibodies to the leukocyte membrane CD18 glycoprotein complex and to intercellular adhesion molecule-1 (ICAM-1) inhibit leukocyte-endothelial adhesion in-vivo. Abstract for the Microcirculatory Society Meeting, Baltimore, 1990.

40. Winquist, R.J., Frei, P., Harrison, P., McFarland, M., Letts, G., Van, G. Andrews, L., Rothlein, R. and Hintze, T.: An anti-CD18 MAb limits infarct size in primates following ischemia and reperfusion. Circulation 82: III-701, 1990, 1990.

41. Weldon, S.M., Rothlein, R., Letts, L.G., Winquist, R.J. and Possanza, G.J.: Neutrophil CD11/CD18 complex plays a role in endotoxin-induced shock in rabbits. Abstract presented at the 5th International Inflammation Research Association Meeting, 1990.

42. Weldon, S.M. and Winquist, R.J.: Comparison of endothelin-1,2 and 3 on microvascular blood flow and permeability in rabbit skin. Blood Vessels 28, 342, 1991.

43. Li, T., Croce, K. and Winquist, R.J.: Regional differences in the effects of septic shock on vascular reactivity in rabbits. Presented at the FASEB Summer Conference on Endothelium and Cardiovascular Function, Copper Mountain, CO, 1991.

44. Frei, P., Kerr, S., Weldon, S., McFarland, M., Harrison, P., Desai, S., Madwed, J., Winquist, R. and Panzenbeck, M.: Depressor response to propranolol is related to the level of plasma renin activity (PRA) in conscious monkeys on a low sodium diet. Physiologist 34, 232, 1991.

45. Madwed, J.B., Panzenbeck, M.P. and Winquist, R.J.: Angiotensin peptides (A1-7 and A2-8) potentiate the pressor response to phenylephrine in anesthetized rabbits. Circulation 84, II-625, 1991.

- 23 -

46. Weldon, S.M. and Winquist, R.J.: Effect of angiotensin peptides on microvascular blood flow and permeability in the rabbit. FASEB, 1992.

47. Li, T., Croce, K. and Winquist, R.J.: Norepinephrine (NE) unmasks vasoconstrictor and vasodilator effects of serotonin (5-HT) in the isolated rabbit kidney. FASEB, 1992.

48. Panzenbeck, M.J., Harrison, P.C., Madwed, J.B., Winquist, R.J., McFarland, M.L. and Desai, S.N.: Sodium depletion in conscious monkeys attenuates baroreflex sensitivity independently of prostaglandin synthesis. XIV Congress of the European Society of Cardiology, 1992.

49. Frei, P.P., Winquist, R.J., Madwed, J.B. and Panzenbeck, M.J.: Marked hypotension following high dose infusion of angiotensin II in rabbits is caused by a decrease in aortic flow. FASEB J. 7: A476, 1993.

50. Kerr, S.W., Madwed, J.B., Frei, P.P., Weldon, S.W., Desai, S., Loughnan, C., Panzenbeck, M.J. and Winquist, R.J.: Effects of losartan (DUP-753) and EXP-3174 on blood pressure, angiotensin II and plasma renin activity in conscious monkeys. FASEB J. 7: A630, 1993.

51. Panzenbeck, M.J., Loughnan, C.L., Fogal, S., Madwed, J.B., and Winquist, R.J.: Captopril-induced hypotension in sodium-depleted, conscious marmosets is prevented by the bradykinin antagonist HOE-140. Hypertension 22: 429, 1993.

52. Weldon, S.M., Winquist, R.J., Panzenbeck, M.J. and Madwed, J.B.: Inhibition of nitric oxide attenuates the acetylcholine-induced hypotensive but not the bradycardic responses in conscious primates. Hypertension 22: 436, 1993.

53. Winquist, R.J., Panzenbeck, M.J., Madwed, J.B., Frei, P.P., Desai, S., Harrison, P., Kerr, S.W., Weldon, S.M., McFarland, M., Wienen, W. and van Meel, J.: The effects of BIBR277, an angiotensin II type 1 receptor antagonist in conscious monkeys. FASEB J 1994.

54. Desai, S., Harrison, P.C., Weldon, S.M., Fogal, S., Loughnan, C., Madwed, J.B., Winquist, R.J. and Panzenbeck, M.J.: Changes in renin concentration, activity and reactivity in response to enalaprilat and AII receptor antagonist in conscious cynomolgus monkeys. FASEB J. 1994.

55. Kerr, S.W., Yu, R., Haynes, N.A. and Winquist, R.J.: Polymorphonuclear leukocyte-induced vasoconstriction in isolated human umbilical veins is blocked by either anti-ICAM-1 or anti-CD18 monoclonal antibodies. FASEB J. 10: A337, 1996.

56. Kerr, S.W. and Winquist, R.J.: Mononuclear leukocyte-induced vasoconstriction in isolated human umbilical veins is attenuated by treatment with cyclosporin A. FASEB J. 11: A337, 1997.

- 24 -

57. Kerr, S.W., Wolyniec, W.W., Filipovic, Z., Braza, F. and Winquist, R.J.: Increased intestinal permeability and the effect of cyclosporin A in an experimental animal model of inflammatory bowel disease in HLA-B27 rats. FASEB J. 12: A737, 1998.

58. Winquist, R.J., Wolyniec, W., Filipovic, Z., Kerr, S., Reilly, P., Nodop, and Noonan, T.: Structural and Functional Assessment of Colitis in HLA-B27 b2 Microglobulin Transgenic Rats. American Gastroenterological Association and American Association for the Study of Liver Diseases, 1998.

59. Fogal, S.E., Kerr, S.W., Giannaras, A., Haynes, N.A., Winquist, R.J. and Panzenbeck, M.J.: Treatment with an anti-LFA-1 antibody significantly decreases delayed-type hypersensitivity (DTH) responses in squirrel monkeys. FASEB J. 14: A1154, 2000.

60. Kerr, S.W., Fogal, S.E., Winquist, R.J. and Panzenbeck, M.J.: In vivo treatment with an anti-CD11a monoclonal antibody (mAb) down-regulates lymphocyte LFA-1 expression in a delayed-type hypersensitivity (DTH) model in non-human primates. FASEB J. 14: A1154, 2000.

61. Franco,R., Dong,L., Galullo,V., Hornsten,A., Pan,J.Q., Sui,J., White,G., Winquist, R. and Zelle,R.: Discovery of novel, orally bioavailable, N-type calcium (Cav2.2) channel blockers for treatment of neuropathic pain. Meeting on “Neuropathic Pain: Changing Paradigms in Diagnosis and Treatment”, Madrid, Spain (May, 2004).

62. Bowen, C., Bridson, G., Heiser, A., Galullo, V., Winquist, R. and Zelle, R.: Novel blockers of Cav2.2: Brain penetration and efficacy in rat models of pain including neuropathic pain. Meeting on “Neuropathic Pain: Changing Paradigms in Diagnosis and Treatment”, Madrid, Spain (May, 2004).

ADVISORY OR PEER REVIEW COMMITTEES

Currently in NIH consultant file for NIH and PHS review.

Ad hoc member on NIH program project site visit team for grant submitted by Dr. Allen Cowley at the Medical College of Wisconsin. April 27 and 28, 1987.

Ad hoc member of NIH program project site visit team for grant submitted by Dr. Neil Ruderman at University Hospital, Boston, MA. February 1-3, 1988.

Ad hoc member on site visit committee to review application from the Clinical Research Institute of Montreal for a MRC Multidisciplinary Research "Group on Hypertension" award. Invited by the Medical Research Council of Canada. May 8 and 9, 1990.

Ad hoc member of Toxicology-1 (AHR-M2) study section for 2R01 GM29840-23A1, June, 1992.

- 25 -

Consultant for review of Merit Review Application Grant 151/NEUR/15 for Department of Veterans Affairs, September, 1992.

Ad hoc reviewer, Musculoskeletal, Oral and Skin Sciences (MOSS) SBIR, Division of Translational and Clinical Sciences, NIH (2011, 2013)

- 26 -

- 27 -